CLEC4C (Myc-DDK-tagged)-Human C-type lectin domain family 4, member C (CLEC4C), transcript variant 2
| Type | Human Tagged ORF Clone |
| Tag | Myc-DDK |
| Vector | pCMV6-Entry |
Products
CLEC4C (Myc-DDK-tagged)-Human C-type lectin domain family 4, member C (CLEC4C), transcript variant 1
| Type | Human Tagged ORF Clone |
| Tag | Myc-DDK |
| Vector | pCMV6-Entry |
- TrueORF®
CLEC4C - KN2.0, Human gene knockout kit via CRISPR, non-homology mediated.
| Format | 2 gRNA vectors, 1 linear donor |
| Donor DNA | EF1a-GFP-P2A-Puro |
Transient overexpression lysate of C-type lectin domain family 4, member C (CLEC4C), transcript variant 2
| Tag | C-Myc/DDK |
| Expression Host | HEK293T |
Anti-CLEC4C Rabbit Polyclonal Antibody
| Applications | IHC |
| Reactivities | Human |
CLEC4C HEK293T cell transient overexpression lysate (as WB positive control)
| Tag | C-Myc/DDK |
| Expression Host | HEK293T |
CLEC4C CRISPRa kit - CRISPR gene activation of human C-type lectin domain family 4 member C
| Format | 3 gRNAs (5ug each), 1 scramble ctrl (10ug) and 1 enhancer vector (10ug) |
qSTAR qPCR primer pairs against Homo sapiens gene CLEC4C
Transient overexpression of CLEC4C, transcript variant 2, in HEK293T cells, FFPE control for IHC, ICC and ISH staining, 25 slides per pack
CLEC4C - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector, 5µg of each construct provided
| Format | Lentiviral plasmids |
| Vector | pGFP-C-shLenti |
CLEC4C - Human, 4 unique 29mer shRNA constructs in retroviral untagged vector, 5µg of each construct provided
| Format | Retroviral plasmids |
| Vector | pRS |
Anti-CLEC4C Rabbit Polyclonal Antibody
| Applications | IHC |
| Reactivities | Human |
Anti-CLEC4C Reference Antibody (LFB patent anti-BDCA-2)
| Applications | Animal Model, ELISA, FACS, FN, Kinetics |
| Reactivities | Human |
Anti-CLEC4C Reference Antibody (BIIB059)
| Applications | Animal Model, ELISA, FACS, FN, Kinetics |
| Reactivities | Human, Cynomolgus |
Anti-Hu CD303 Purified
| Applications | ELISA, FC, ICC, IHC |
| Reactivities | Human |
